On 9 July 2025, the Amsterdam District Court ruled that the Pharmaceutical Accountability Foundation (PAF) lacked standing in its collective claim against AbbVie regarding the sale of Humira® (adalimumab) in the Netherlands, finding that PAF did not hold the requisite interest in the claim.
PAF commenced proceedings against AbbVie in February 2023, alleging that AbbVie acted unlawfully by overcharging for Humira®, leading to the displacement of publicly insured health services and violating fundamental human rights under Article 2 of the European Convention on Human Rights, and further breached relevant competition laws by abusing its market power.
In a statement released on 9 July 2025, PAF says that it had estimated that AbbVie “earned as much as €1 billion in excess profit in the Netherlands, costing the health system an equivalent of 13,950 years of healthy life”, and that it was “disappointed that the court did not address the merits of [the] case”. PAF is considering an appeal.